TY - JOUR
T1 - RANKL employs distinct binding modes to engage RANK and the osteoprotegerin decoy receptor
AU - Nelson, Christopher A.
AU - Warren, Julia T.
AU - Wang, Michael W.H.
AU - Teitelbaum, Steven L.
AU - Fremont, Daved H.
N1 - Funding Information:
We thank the MBC-CAT team at ALS for assistance in crystallographic data collection. This work was supported by the National Institutes of Health Grant Numbers AR032788 (to S.L.T. and D.H.F.) and F30 AG039896 (to J.T.W.).
PY - 2012/11/7
Y1 - 2012/11/7
N2 - Osteoprotegerin (OPG) and receptor activator of nuclear factor κB (RANK) are members of the tumor necrosis factor receptor (TNFR) superfamily that regulate osteoclast formation and function by competing for RANK ligand (RANKL). RANKL promotes osteoclast development through RANK activation, while OPG inhibits this process by sequestering RANKL. For comparison, we solved crystal structures of RANKL with RANK and RANKL with OPG. Complementary biochemical and functional studies reveal that the monomeric cytokine-binding region of OPG binds RANKL with ∼500-fold higher affinity than RANK and inhibits RANKL-stimulated osteoclastogenesis ∼150 times more effectively, in part because the binding cleft of RANKL makes unique contacts with OPG. Several side chains as well as the C-D and D-E loops of RANKL occupy different orientations when bound to OPG versus RANK. High affinity OPG binding requires a 90s loop Phe residue that is mutated in juvenile Paget's disease. These results suggest cytokine plasticity may help to fine-tune specific tumor necrosis factor (TNF)-family cytokine/receptor pair selectivity.
AB - Osteoprotegerin (OPG) and receptor activator of nuclear factor κB (RANK) are members of the tumor necrosis factor receptor (TNFR) superfamily that regulate osteoclast formation and function by competing for RANK ligand (RANKL). RANKL promotes osteoclast development through RANK activation, while OPG inhibits this process by sequestering RANKL. For comparison, we solved crystal structures of RANKL with RANK and RANKL with OPG. Complementary biochemical and functional studies reveal that the monomeric cytokine-binding region of OPG binds RANKL with ∼500-fold higher affinity than RANK and inhibits RANKL-stimulated osteoclastogenesis ∼150 times more effectively, in part because the binding cleft of RANKL makes unique contacts with OPG. Several side chains as well as the C-D and D-E loops of RANKL occupy different orientations when bound to OPG versus RANK. High affinity OPG binding requires a 90s loop Phe residue that is mutated in juvenile Paget's disease. These results suggest cytokine plasticity may help to fine-tune specific tumor necrosis factor (TNF)-family cytokine/receptor pair selectivity.
UR - http://www.scopus.com/inward/record.url?scp=84868567803&partnerID=8YFLogxK
U2 - 10.1016/j.str.2012.08.030
DO - 10.1016/j.str.2012.08.030
M3 - Article
C2 - 23039992
AN - SCOPUS:84868567803
SN - 0969-2126
VL - 20
SP - 1971
EP - 1982
JO - Structure
JF - Structure
IS - 11
ER -